Why Did DEA Conclude That Buprenorphine Should Be Placed in Schedule III of the Controlled Substances Act?
The DEA found that buprenorphine met the definition of a Schedule III substance. In accordance with 21 U.S.C. 812(b): 1. Buprenorphine has a potential for abuse less than the drugs or other substances in Schedule I or II. Buprenorphine is a long-acting partial agonist with a high affinity for and slow dissociation from opioid receptors. Buprenorphine produces effects similar to other pure mu agonists (like morphine or hydromorphone) including euphoria, drug liking, respiratory depression, pupillary constriction and sedation. It is recognized as morphine or heroin-like by experienced narcotic abusers. Little abuse or diversion of buprenorphine has been noted in the U.S. (reflecting very limited prescription, distribution and product formulation: only low-dose injectable buprenorphine has been marketed). However, significant abuse of buprenorphine has been reported in many countries where it has been more available and other formulations have been marketed. In those countries, buprenorph
Related Questions
- What is the procedure in North Carolina for physicians when ordering Schedule II, III, and IV controlled substances for office use?
- Why Did DEA Conclude That Buprenorphine Should Be Placed in Schedule III of the Controlled Substances Act?
- Is it possible for an Internet pharmacy to fill prescriptions for Schedule III-V controlled substances?
